专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP1513817A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY 审中-公开
标题翻译：的降血糖1,2-吡咯衍生物具有与效果HYPOLIPIDEMISCHER
公开(公告)号：EP1513817A1
公开(公告)日：2005-03-16
申请号：EP03730575.2
申请日：2003-05-22
申请人： Takeda Pharmaceutical Company Limited
发明人： MAEKAWA, Tsuyoshi , HARA, Ryoma , ODAKA, Hiroyuki , KIMURA, Hiroyuki , MIZUFUNE, Hideya , FUKATSU, Kohji
IPC分类号： C07D231/12 , C07D261/08 , C07D401/04 , C07D413/12 , A61K31/4155 , A61K31/415 , A61K31/42 , A61K31/422 , A61K31/4439 , C07D231/14 , C07D231/20 , C07D231/22 , C07D401/14 , C07D403/04 , C07D403/14
CPC分类号： C07D231/12 , C07D231/14 , C07D231/20 , C07D231/22 , C07D261/08 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D413/12 , C07D417/04
摘要： A compound represented by the formula (1) wherein ring A is a ring optionally having 1 to 3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, - O -, - S - and the like; Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; ring C is a monocyclic aromatic ring which may further have 1 to 3 substituents; and R represents -OR4 (R4 is hydrogen atom or optionally substituted hydrocarbon group) and the like, or a salt thereof or a prodrug thereof is useful as an agent for the prophylaxis or treatment of diabetes and the like.

2. 发明授权

EP0885210B2 Tricylic compounds having binding affinity for melatonin receptors, their production and use 失效
标题翻译：具有用于褪黑激素受体，它们的制备和使用的结合亲和力的三环化合物
公开(公告)号：EP0885210B2
公开(公告)日：2008-06-18
申请号：EP97905450.9
申请日：1997-03-05
申请人： Takeda Pharmaceutical Company Limited
发明人： OHKAWA, Shigenori , UCHIKAWA, Osamu , FUKATSU, Kohji , MIYAMOTO, Masaomi
IPC分类号： C07D307/93 , C07D311/94 , C07D491/04 , A61K31/40 , A61K31/34 , C07D317/70 , C07D263/56 , C07D263/58 , C07D265/34
CPC分类号： C07D263/52 , C07D265/34 , C07D307/93 , C07D311/94 , C07D317/70 , C07D319/14 , C07D491/04 , Y10S514/923
摘要： A compound of formula (I) wherein R1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R2 is H or an optionally substituted hydrocarbon group; R3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR4, NR4, O or S in which R4 is H or an optionally substituted hydrocarbon group; Y is C, CH or N; ring A is an optionally substituted 5- to 7-membered ring; ring B is an optionally substituted benzene ring; and m is 1 to 4, or a salt thereof, a process for producing it, an intermediate for the production and a pharmaceutical composition comprising it are provided.

3. 发明公开

EP2123652A1 HETEROCYCLIC COMPOUND 审中-公开
标题翻译：杂志VERBINDUNG
公开(公告)号：EP2123652A1
公开(公告)日：2009-11-25
申请号：EP08711532.5
申请日：2008-02-19
申请人： Takeda Pharmaceutical Company Limited
发明人： FUKATSU, Kohji , KAMATA, Makoto , YAMASHITA, Tohru
IPC分类号： C07D471/10 , A61K31/438 , A61K31/537 , A61P1/00 , A61P1/12 , A61P1/16 , A61P3/00 , A61P3/04 , A61P3/06 , A61P3/10 , A61P5/48 , A61P7/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P13/12 , A61P15/00 , A61P19/10 , A61P21/04 , A61P25/16
CPC分类号： C07D471/10 , C07D491/107 , C07D495/10 , C07D498/10 , C07D519/00
摘要： The present invention provides a compound having an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy.
The present invention provides a compound represented by the formula (I):

wherein each symbol is as in the specification, or a salt thereof.
摘要翻译：本发明提供具有ACC抑制作用的化合物，其可用于预防或治疗肥胖，糖尿病，高血压，高脂血症，心力衰竭，糖尿病并发症，代谢综合征，肌肉减少症，癌症等，并且具有优异的疗效。本发明提供由式（I）表示的化合物：其中每个符号如说明书中所述，或其盐。

4. 发明公开

EP1559422A1 RECEPTOR FUNCTION CONTROLLING AGENT 有权
标题翻译： MITTEL ZUR KONTROLLE DER REZEPTORFUNKTION
公开(公告)号：EP1559422A1
公开(公告)日：2005-08-03
申请号：EP03810621.7
申请日：2003-11-06
申请人： Takeda Pharmaceutical Company Limited
发明人： FUKATSU, Kohji , SASAKI, Shinobu , HINUMA, Shuji , ITO, Yasuaki , SUZUKI, Nobuhiro , HARADA, Masataka , YASUMA, Tsuneo
IPC分类号： A61K31/192
CPC分类号： C07C255/24 , A61K31/192 , A61K31/195 , A61K31/216 , A61K31/343 , A61K31/381 , A61K31/401 , A61K31/404 , A61K31/426 , A61K31/428 , A61K31/437 , C07C59/64 , C07C59/68 , C07C59/72 , C07C59/74 , C07C59/76 , C07C59/90 , C07C65/24 , C07C69/734 , C07C69/736 , C07C217/48 , C07C217/58 , C07C217/76 , C07C235/42 , C07C255/54 , C07C317/28 , C07C323/19 , C07C2601/02 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07C2602/12 , C07D209/12 , C07D277/36 , C07D277/42 , C07D277/64 , C07D295/13 , C07D307/91 , C07D333/32 , C07D333/54 , C07D333/62 , C07D333/78 , C07D471/04
摘要： The GPR40 receptor function regulator of the present invention, which comprises a compound having an aromatic ring and a group capable of releasing cation is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.
摘要翻译：本发明的GPR40受体功能调节剂，其包含具有芳香环的化合物和能够释放阳离子的基团，可用作胰岛素促分泌素或预防或治疗糖尿病等的药剂。

5. 发明公开

EP2009011A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND 审中-公开
标题翻译：含氮的杂环化合物
公开(公告)号：EP2009011A1
公开(公告)日：2008-12-31
申请号：EP07741635.2
申请日：2007-04-13
申请人： Takeda Pharmaceutical Company Limited
发明人： FUKATSU, Kohji , KAMATA, Makoto , YAMASHITA, Tohru , ENDO, Satoshi
IPC分类号： C07D409/06 , A61K31/4535 , A61K31/5377 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/04 , A61P9/12 , A61P21/00 , A61P43/00 , C07D409/14 , C07D413/14 , C07D417/14 , C12N9/99 , C12N15/09
CPC分类号： C07D401/04 , C07D409/06 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The object of the present invention is to provide a compound having an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and has superior properties such as efficacy, duration of activity, specificity, low toxicity and the like.
The present invention provides a compound represented by the following formula

wherein
ring M is a 5- or 6-membered aromatic ring;
W is C or N;
K is an optionally substituted methylene group or an optionally substituted imino group;
R is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxy group or an optionally substituted heterocyclic group;
T and U are independently a hydrogen atom or a substituent or, T and U form, together with ring M, an optionally substituted bicyclic ring;
D and G are independently a carbonyl group or a sulfonyl group; ring P is an optionally substituted piperidine or an optionally substituted piperazine;
B is CH or N;
ring Q is an optionally substituted monocyclic ring;
A is C, CH or N; and
J is an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted amino group,
provided that when the W moiety of ring M is =N- or -N=, then U should be absent,
or a salt thereof.
摘要翻译：本发明的目的是提供可用于预防或治疗肥胖症，糖尿病，高血压，高脂血症，心力衰竭，糖尿病并发症，代谢综合症，肌肉减少症等的具有ACC抑制作用的化合物，诸如功效，活性持续时间，特异性，低毒性等优越特性。本发明提供由下式表示的化合物，其中环M为5元或6元芳环; W是C或N; K是任选取代的亚甲基或任选取代的亚氨基; R为氢原子，任选取代的烃基，任选取代的羟基或任选取代的杂环基; T和U独立地为氢原子或取代基，或者T和U形式与环M一起为任选取代的双环; D和G独立地为羰基或磺酰基; 环P是任选取代的哌啶或任选取代的哌嗪; B是CH或N; 环Q是任选取代的单环; A是C，CH或N; 并且J是任选取代的烃基，任选取代的杂环基或任选取代的氨基，条件是当环M的W部分是= N-或-N =时，则U应当不存在或其盐。

7. 发明公开

EP2128163A1 SPIRO-RING COMPOUND 审中-公开
标题翻译： RINGFÖRMIGESPIROVERBINDUNGEN
公开(公告)号：EP2128163A1
公开(公告)日：2009-12-02
申请号：EP08703778.4
申请日：2008-01-24
申请人： Takeda Pharmaceutical Company Limited
发明人： FUKATSU, Kohji , KAMATA, Makoto , YAMASHITA, Tohru
IPC分类号： C07D519/00 , A61K31/4545 , A61K31/695 , A61P1/00 , A61P1/04 , A61P1/12 , A61P1/14 , A61P1/16 , A61P1/18 , A61P3/04 , A61P3/06 , A61P3/10 , A61P7/00 , A61P7/02 , A61P7/10 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/04 , A61P13/10
CPC分类号： C07F7/1856 , C07D495/04 , C07D498/10 , C07D519/00
摘要： The present invention aims to provide a compound having an acetyl-CoA carboxylase (ACC) inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy.
The present invention provides a compound represented by the formula (I):

wherein
R 1 is a hydrogen atom or a substituent;
ring P is an optionally substituted 6-membered nitrogen-containing aromatic heterocycle;
ring Q is an optionally further substituted 5- to 7-membered nitrogen-containing non-aromatic heterocycle; and
ring R is an optionally fused 5- to 7-membered non-aromatic ring, which is further optionally substituted,
or a salt thereof.
摘要翻译：本发明旨在提供一种具有乙酰-CoA羧化酶（ACC）抑制作用的化合物，其可用于预防或治疗肥胖症，糖尿病，高血压，高脂血症，心力衰竭，糖尿病并发症，代谢综合征，肌肉减少症，癌症和并具有优越的疗效。本发明提供由式（I）表示的化合物：其中R 1是氢原子或取代基; 环P是任选取代的6元含氮芳族杂环; 环Q是任选进一步取代的5-至7-元含氮非芳族杂环; 并且环R是任选稠合的5至7元非芳族环，其进一步任选被取代，或其盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式